In the context of amyotrophic lateral sclerosis (ALS), another neurodegenerative disorder, two recent cross-sectional case–control studies examined the role of metabolic biomarkers, including GLP-1, in the progression and pathogenesis of ALS [65, 66]. This evidence concerns the gene GLP1R and amyotrophic lateral sclerosis.